

## Q-linea sponsored health economics study enrolls first patient

Q-linea AB (publ) (OMX: QLINEA) – Q-linea today announces that the first patient has been enrolled in Lifetimes, a Q-linea sponsored multicentre study investigating the health and economic benefits of using ASTar when treating ICU patients with bloodstream infections.

The study will enroll 160 prospective ICU patients, including adults and children, treated for Gram-negative bacteraemia at four major Italian hospitals. The study aims to investigate the impact of using ASTar on time to optimal therapy, ICU and hospital length of stay, duration, and cost of antibiotic therapy. It is expected to last approximately one year.

“The Lifetimes study is an important milestone in Q-linea’s clinical strategy. ASTar is expected to improve quality-adjusted life years (QALYs), enhance antimicrobial stewardship programs, reduce hospital costs, and streamline laboratory workflow”, said Tiziana Di Martino, CMO of Q-linea.

“We are thrilled to announce the start of the first health economic study sponsored by Q-linea. By proving the impact of ASTar utilisation on patient outcomes and healthcare-associated costs, we are convinced ASTar implementation rate will increase saving more lives in the future”, said Jonas Jarvius, CEO of Q-linea.

### **About ASTar Instruments and ASTar BC G-Kit**

ASTar Instrument and ASTar BC G-Kit already deliver the broadest answer regarding the combination of the number of antibiotics and the number of double dilution steps of each antibiotic, in a single analysis for gram-negative bacteria. The test enables the analysis of gram-negative bacteria, including difficult-to-grow so-called fastidious bacteria, which satisfies the need for rapid and comprehensive results to support optimal treatment decisions.

ASTar Instrument and ASTar BC G-Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States.

### **For more information, please contact:**

Jonas Jarvius, CEO, Q-linea AB

[Jonas.Jarvius@qlinea.com](mailto:Jonas.Jarvius@qlinea.com)

+46 (0) 70-323 77 60

Christer Samuelsson, CFO /IR, Q-linea AB

[Christer.Samuelsson@qlinea.com](mailto:Christer.Samuelsson@qlinea.com)

+46 (0) 70-600 15 20

## About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar<sup>®</sup> is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit [www.qlinea.com](http://www.qlinea.com).

## Attachments

[Q-linea sponsored health economics study enrolls first patient](#)